|
In the position of Chief Scientific Officer, Dr. Brownstein brings over thirty years of research experience in the fields of genetics, endocrinology and pharmacology and to the company’s drug development program. Dr. Brownstein joined the National Institute of Health (NIH) where, after serving as Chief of the Laboratory of Cell Biology of the National Institute of Mental Health (NIMH) he was then appointed Chief of the Laboratory of Genetics of the NIMH and the National Human Genome Research Institute. He has since directed the functional genomics program at the J. Craig Venter Institute in Rockville, MD. While at the NIMH, he directed the work in Bethesda on the Brain Molecular Anatomy Project, the goal of which was to catalog genes expressed in the nervous system. Simultaneously, he contributed to the Mammalian Gene Collection, a trans-Institutional effort to clone and sequence cDNAs corresponding to all human, mouse, and rat transcripts. He went to the National Institute of Health to work with Julius Axelrod, recipient of a Nobel Prize in 1970 for his work in the field of neuropharmacology, and stayed there after completing his fellowship. He has worked in the fields of neurobiology, neuroendocrinology, biochemical pharmacology, genetics, and genomics, and is especially interested in developing novel diagnostic tools and therapeutic agents. He has published more than 200 papers in peer reviewed journals, has served on several editorial boards and has served and continues to serve on several scientific advisory boards including the Lawrence Livermore National Laboratory and the Translational Genomics Research Institute. He has also participated in founding several successful bio-pharmaceutical companies. Dr. Brownstein earned his bachelor's degree from Columbia University and completed his medical training at University of Chicago, where he received his M.D. and Ph.D. in pharmacology. | 